Gregory A Demopulos

Type: Person
Name: Gregory A Demopulos
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

OMEROS : to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference

By a News Reporter-Staff News Editor at Biotech Week -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous ... [Published 4 Traders - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Omeros reports net loss of $18 million for second quarter 2014

Injecting vaccine-like compound into mice effective in protecting from malariaNGS issues positive coverage decision for PTNS to manage symptoms of OABNew approach to knocking out parasite's genesForecast report on U.S. Orthopedic Large Joint Reconstruction ... [Published News-Medical.Net - Aug 12 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 3 reports

Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference

SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today ... [Published Nasdaq - Aug 08 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

OMEROS : Assigned Patent

By Targeted News ServiceALEXANDRIA, Va. , Aug. 1 -- Omeros , Seattle , has been assigned a patent (8,790,696) developed by four co-inventors for a "[c]yclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological ... [Published 4 Traders - Aug 01 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 1 reports

Omeros receives FDA approval of Omidria

Seattle— The FDA has approved Omeros’ phenylephrine and kertorolac injection (Omidria) 1%/0.3% for use during cataract surgery or IOL replacement (ILR) to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain.The approval ... [Published Modern Medicine - Jun 02 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

Omeros reports additional positive data from OMS824 Phase IIa schizophrenia clinical trial

Omeros has announced additional positive results from a Phase IIa clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor.Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which ... [Published Pharmaceutical Business Review - Mar 07 2014]

More Content

All (12) | News (10) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
OMEROS : to Present at the Wedbush PacGrow 2014... [Published 4 Traders - Aug 13 2014]
Omeros reports net loss of $18 million for seco... [Published News-Medical.Net - Aug 12 2014]
Omeros Corporation Reports Second Quarter 2014 ... [Published TickerTech.com - Aug 11 2014]
Omeros to Present at the Wedbush PacGrow 2014 L... [Published Nasdaq - Aug 08 2014]
Omeros to Present at the Wedbush PacGrow 2014 L... [Published Good Day Sacramento - Aug 08 2014]
Omeros to Present at the Wedbush PacGrow 2014 L... [Published PR Newswire: Health - Aug 08 2014]
OMEROS : Assigned Patent [Published 4 Traders - Aug 01 2014]
Omeros receives FDA approval of Omidria [Published Modern Medicine - Jun 02 2014]
Omeros reports additional positive data from OM... [Published Pharmaceutical Business Review - Mar 07 2014]
Omeros to Present at Cowen and Company 34th Ann... [Published PR Newswire: General Business - Feb 26 2014]
Omeros doses 1st patient in second phase II cli... [Published PharmaBiz - Feb 21 2014]
Omeros' lead human monoclonal antibody, OMS721 ... [Published PharmaBiz - Dec 21 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Omeros to Present at the Wedbush PacGrow 2014 L... [Published PR Newswire: Health - Aug 08 2014]
SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today ...
Omeros to Present at Cowen and Company 34th Ann... [Published PR Newswire: General Business - Feb 26 2014]
SEATTLE, Feb. 26, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.